Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R | Q15722 | 4/20 | 0.48 |
| ▸ | DAO | P14920 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | PRNP | P04156 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.40 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2399697 | 0.89 | DAO (0.47) | LTB4RDAOALDH1A1SMN1; SMN2NPSR1 | |
| SCHEMBL10695926 | 0.84 | DAO (0.39) | LTB4RDAOALDH1A1SMN1; SMN2TSHR | |
| SCHEMBL2033883 | 0.80 | CYP1A2 (0.43) | DAOALDH1A1SMN1; SMN2TSHRPOLB | |
| SCHEMBL15135063 | 0.79 | HSD17B10 (0.51) | LTB4RDAOALDH1A1LMNAPRNP | |
| SCHEMBL8855371 | 0.78 | DAO (0.42) | LTB4RDAOALDH1A1LMNARECQL | |
| SCHEMBL8588999 | 0.77 | DAO (0.32) | LTB4RDAOKDM4C | |
| SCHEMBL81915 | 0.77 | DAO (0.36) | DAOKDM4CPOLB | |
| SCHEMBL1551106 | 0.77 | DAO (0.50) | DAOALDH1A1RECQLSMN1; SMN2TSHR | |
| SCHEMBL8540112 | 0.76 | DAO (0.41) | LTB4RDAOALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL12468530 | 0.76 | LTB4R (0.43) | LTB4RDAOALDH1A1RXFP1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630521-B2 | Arylamides and methods of use thereof | GENZYME CORPORATION (US) | 2026-05-19 | — | — | US | disclosed |
| US-20260034093-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SUMITOMO PHARMA AMERICA, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| US-20240358675-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SUMITOMO PHARMA AMERICA, INC. (US) | 2024-10-31 | — | — | US | disclosed |
| CN-118165002-A | Polycyclic compounds and methods of use thereof | 桑诺维恩药品公司 | 2024-06-11 | — | — | CN | disclosed |
| EP-3252057-B1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC (US) | 2024-03-27 | — | — | EP | disclosed |
| US-20230147360-A1 | ARYLAMIDES AND METHODS OF USE THEREOF | GENZYME CORPORATION | 2023-05-11 | — | — | US | disclosed |
| US-20230147360-A1 | ARYLAMIDES AND METHODS OF USE THEREOF | GENZYME CORPORATION | 2023-05-11 | — | — | US | disclosed |
| US-20230147360-A1 | ARYLAMIDES AND METHODS OF USE THEREOF | GENZYME CORPORATION | 2023-05-11 | — | — | US | disclosed |
| US-20220387382-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2022-12-08 | — | — | US | disclosed |
| US-20220387382-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2022-12-08 | — | — | US | disclosed |
| EP-2507245-A2 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | Sunovion Pharmaceuticals Inc. (US) | 2012-10-10 | — | — | EP | disclosed |
| WO-2011069063-A2 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS, INC. (US) | 2011-06-09 | — | — | WO | disclosed |
| WO-2011069063-A2 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SUNOVION PHARMACEUTICALS, INC. (US) | 2011-06-09 | — | — | WO | disclosed |
| US-20040142976-A1 | Pyridylfuran and pyridylthiophene compounds | PFIZER INC. | 2004-07-22 | — | — | US | disclosed |
| US-6696470-B2 | FOR THERAPY OF ARTHRITIS, ASTHMA, BONE RESORPTION DISEASE, CACHEXIA, CARDIOVASCULAR DISEASE, CEREBRAL MALARIA, CROHN'S DISEASE, DIABETES, FEVER OR MYALGIA DUE TO INFECTION, GOUT, GRAFT VERSUS HOST REACTION, INFLAMMATION OF ORGANS, ETC. | PFIZER INC. | 2004-02-24 | — | — | US | disclosed |
| US-20020022729-A1 | Pyridylfuran and pyridylthiophene compounds | KAWAI AKIYOSHI (JP) | 2002-02-21 | — | — | US | disclosed |
| EP-0853083-B1 | Pyridylfuran and pyridylthiophene compounds and pharmaceutical use thereof | PFIZER (US) | 2001-09-12 | — | — | EP | disclosed |
| US-6048880-A | THERAPY FOR CYTOKINE SENSITIVE DISEASES | PFIZER PHARAMACEUTICALS INC. (JP) | 2000-04-11 | — | — | US | disclosed |
| EP-0853083-A1 | Pyridylfuran and pyridylthiophene compounds and pharmaceutical use thereof | PFIZER INC. (US) | 1998-07-15 | — | — | EP | disclosed |
| EP-0267439-A2 | Alpha-(phenylalkyl) pyridinealkanol derivatives | G.D. Searle & Co. (US) | 1988-05-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220387382-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | GRIN2C, NLN, COMT | LTB4R 1684/4885DAO 1113/4885ALDH1A1 919/4885 |
| US-20240358675-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | GRIN2C, NLN, COMT | LTB4R 1684/4885DAO 1113/4885ALDH1A1 919/4885 |
| US-20230147360-A1 | ARYLAMIDES AND METHODS OF USE THEREOF | CFTR, AADAC, ARSA | LTB4R 1848/4885DAO 1945/4885ALDH1A1 1072/4885 |
| US-12630521-B2 | Arylamides and methods of use thereof | CFTR, CLIC1, CLCN2 | LTB4R 2768/4885DAO 2917/4885ALDH1A1 905/4885 |
| US-20040142976-A1 | Pyridylfuran and pyridylthiophene compounds | MC2R, FCGR2A, OGFR | LTB4R 45/4885DAO 896/4885ALDH1A1 789/4885 |
| US-20020022729-A1 | Pyridylfuran and pyridylthiophene compounds | MC2R, CRHR1, NR3C2 | LTB4R 59/4885DAO 940/4885ALDH1A1 729/4885 |
| US-20260034093-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USE THEREOF | SLC6A3, SLC6A11, SLC6A13 | LTB4R 4344/4885DAO 2975/4885ALDH1A1 1362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.